Moreover, in in vitro and in NOD/SCID mouse models, lenalidomide blocked the adverse effects of both IL-6 and TGF-β1, adjuvating the anti-tumor effect of anti-GD2 immunotherapy [84]. Here, IL6 is linked to neoplasm.